You are here: Home » News-CM » Equities » Hot Pursuit
Business Standard

Dr Reddy's Lab launches Favipiravir generic in India

Capital Market 

The drug major during market hours today (19 August 2020) announced the launch of AVIGAN (Favipiravir) 200 mg tablets in India.

The drug has been approved by the Drugs Controller General of India (DCGI) for the treatment of patients with mild to moderate COVID-19 disease.

The launch is part of the global licensing agreement with FUJIFILM Toyama Chemical Co. that grants Dr. Reddy's the exclusive rights to manufacture, sell and distribute AVIGAN (Favipiravir) 200 mg Tablets in India, the company said in the BSE filing. The drug comes in a complete therapy pack of 122 tablets with a two-year shelf life.

M V Ramana, Chief Executive Officer, branded markets (India and Emerging Markets), Dr. Reddy's Laboratories, said, "We are pleased to bring this important innovator medicine to the patients in India. The need for high quality and efficacy, affordability and better disease management are key priorities for us. We believe that AVIGAN would provide an effective treatment option to the COVID-19 impacted patients in India."

Dr. Reddy's Laboratories is an integrated pharmaceutical company. The drug major's consolidated net profit declined 12.59% to Rs 579.30 crore on 14.93% jump in revenue from operations to Rs 4,417.50 crore in Q1 June 2020 over Q1 June 2019. Current tax expenses for the quarter jumped 60.04% at Rs 299.60 crore as against Rs 187.20 crore in Q1 June 2019.

The scrip rose 0.05% to Rs 4506.30 on the BSE. It traded in the range of 4494.40 & 4559 so far during the day.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Wed, August 19 2020. 14:07 IST